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Abstract 26 
Despite recent successful control efforts, malaria remains a leading global health 27 
burden. Alarmingly, resistance to current antimalarials is increasing, and the development of 28 
new drug families is needed to maintain malaria control. Current antimalarials target the 29 
intra-erythrocytic developmental stage of the Plasmodium falciparum life cycle. However, 30 
the invasive extracellular parasite form, the merozoite, is also an attractive target for drug 31 
development. We have previously demonstrated that heparin-like-molecules, including those 32 
with low molecular weights and low anti-coagulant activities are potent and specific 33 
inhibitors of merozoite invasion and blood-stage replication. Here we tested a large panel of 34 
heparin-like-molecules and sulfated polysaccharides together with various modified chemical 35 
forms for inhibitory activity against P. falciparum merozoite invasion. We identified 36 
chemical modifications that improve inhibitory activity and identified several additional 37 
sulfated polysaccharides with strong inhibitory activity. These studies have important 38 
implications for the further development of heparin-like-molecules as anti-malarial drugs, 39 
and for understanding merozoite invasion. 40 
 41 
INTRODUCTION 42 
Despite gains in malaria control, and a push to elimination in some areas, malaria 43 
remains a significant disease globally with Plasmodium falciparum the leading cause of 44 
malaria (1). Recent evidence of the emergence and spread of artemisinin resistance in several 45 
countries raises concerns that current therapies will lose their clinical value (2), making 46 
continued drug discovery and development a high priority. Malaria disease occurs during 47 
blood stage infection by P. falciparum in which the merozoite form of the parasite invades 48 
and replicates within red blood cells (RBCs). All current drugs including the artemisinin class 49 
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target the intra-RBC stage of development (3). However, targeting and blocking merozoite 50 
invasion also presents an attractive approach for therapeutics to prevent parasite invasion of 51 
RBCs, reducing parasite burden and disease (4, 5). Compounds that block invasion may be 52 
valuable in combination with current drugs providing activity at different stages of the blood-53 
stage life cycle, and drug combinations are increasingly used for various infections to 54 
maximize efficacy and reduce the risk of developing drug resistance. 55 
Merozoite invasion involves numerous receptor-ligand interactions, with multiple, 56 
redundant invasion pathways being identified (6). Nevertheless, sulfated carbohydrates and 57 
heparin-like-molecules (HLMs) have been identified as a group of compounds that block 58 
essential invasion events and are able to inhibit multiple invasion pathways (7). Inhibitory 59 
HLMs include heparin (7, 8), curdlan sulfate (9, 10), polyvinyl-sulfonate sodium salt (11), 60 
suramin (12), carrageenans (13), sulfated cyclodextrins (14), fucosylated chondroitin sulfate 61 
(15) and K5 polysaccharides (7). The ability of HLMs to disrupt invasion maybe due to the 62 
targeting by HLMs of multiple essential or important merozoite ligands. Merozoite invasion 63 
into RBCs proceeds through a number of steps; i) initial contact and weak deformation of the 64 
RBC involving merozoite surface antigens, ii) strong deformation of the RBC involving 65 
microneme and rhoptry proteins and the actin-myosin motor of the parasite, iii) pore opening 66 
between the parasite and the RBC, iv) tight-junction formation between the parasite and RBC 67 
and v) internalization (16). HLMs bind proteins involved ‘pre-invasion’ and initial 68 
attachment stages to the RBC such as merozoite surface protein 1 (MSP1) (7), along with 69 
rhoptry and microneme proteins involved in reorientation and signalling steps of invasion 70 
that trigger strong deformation of the RBCs (17-19). Although the precise mechanisms of 71 
action are not known, it is possible these merozoite proteins interact with sulfate groups on 72 
the RBC surface and HLMs may inhibit invasion by disrupting essential receptor-ligand 73 
interactions. Whilst heparin has the capacity to inhibit at multiple invasion steps, it appears 74 
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that the dominant inhibitory activity of HLMs is mediated at the early invasion stages as 75 
demonstrated with live-video microscopy of merozoite invasion that heparin blocks ‘pre-76 
invasion’ steps (7, 16). However, the capacity of HLMs to also bind proteins involved in 77 
down-stream invasion steps may also contribute to effective inhibition and the observed 78 
inability to select for heparin resistant parasites lines (7). Of further potential therapeutic 79 
benefit, HLMs are also known to disrupt both rosetting and sequestration of infected RBCs 80 
(15, 20-26), which are important mediators of pathogenesis. The ability of HLMs to inhibit 81 
both merozoite invasion and sequestration/rosetting highlights the potential of these 82 
molecules to reduce parasitemia and disease severity. Owing to the anticoagulant activity of 83 
heparin it cannot be used as an antimalarial agent. However, it may be possible to reduce 84 
anticoagulant activity of HLMs while maintaining inhibition of P. falciparum (7). Indeed, 85 
curdlan sulfate, which has a ten-fold reduced anticoagulation activity compared to heparin, 86 
has been tested in a small human trial which suggested that treatment reduced malaria disease 87 
severity (27). Further, HLMs such as K5 polysaccharides, as well as other polyanions that 88 
lack anticoagulant activity have been proposed as potential therapeutics for viral diseases 89 
(reviewed in (28)), and can inhibit merozoite invasion (7).   90 
In previous work, we identified a number of key structural features of HLMs for 91 
invasion-inhibitory activity by testing chemically modified K5-polysaccarides and heparins 92 
together with their oligosaccharides (7). Our findings suggest the importance of N- and O- 93 
sulfate residues, 2 sulfate units per disaccharide, specific spatial arrangements of sulfation 94 
requiring sulfate groups positioned together on a single saccharide unit, and a minimum chain 95 
length of 6 monosaccharide residues for optimal inhibitory activity (7). Structure/function 96 
studies have also successfully been used to develop small drug HLMs for other clinical 97 
applications, such as the pentasaccharide anticoagulant fondaparinux (29). Here we build on 98 
this knowledge by testing HLMs with specific modifications to further investigate structural 99 
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features that mediate high inhibitory activity and identify chemical modifications that 100 
increase activity. Further, we tested a large panel of sulfated polysaccharides prepared from a 101 
wide range of sources to identify inhibitory compounds. We aimed to identify compounds 102 
with strong invasion inhibitory activity that may have potential for therapeutic development. 103 
 104 
MATERIALS AND METHODS 105 
Parasite culture  106 
 P. falciparum 3D7 or D10-PfGFP isolates (30) were cultured as described (31, 32), in 107 
culture media of RPMI-HEPES (pH 7.4) supplemented with 50 g/ml hypoxanthine, 20 108 
g/ml gentamicin, 25 mM sodium bicarbonate (NaHCO3) and 0.5% Albumax II (Gibco). 109 
RBCs from group O+ blood donors were used to culture parasites. Cultures were gassed with 110 
1% O2, 4% CO2, 95% N2 and incubated at 37C. Parasites were initially synchronized using 111 
5% D-sorbitol-treatment for 5 minutes, as described (33). For invasion-inhibition assays, 112 
sorbitol treatment cultures were further synchronised using heparin synchronization; heparin 113 
cannot be used for the selection of heparin resistant cultures therefore it is unlikely that 114 
heparin synchronization affected the testing of HLMs (7). Live video filming of merozoite 115 
invasion was performed as described (7, 34). 116 
Growth inhibition assays and invasion inhibition assays 117 
 High throughput growth inhibition assays were performed as described (30, 32, 35, 118 
36). Duplicate suspensions of synchronised parasites at 2% parasitemia and 1% hematocrit 119 
were incubated with compounds in 96 well sterile U-bottom plates (Falcon) for 44 hours for 120 
one-cycle assays, or 72 hours for two-cycle assays and analysed by flow cytometry with 121 
staining of parasites with 10 µg/ml ethidium bromide (BioRad) for one hour in darkness. 122 
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Parasitemia was measured using BD FACSCalibur or BD FACSCantoII flow cytometer. 123 
Samples were analysed using FlowJo (Tree Star) gating on intact RBCs and then determining 124 
parasitemia by ethidium bromide positive RBCs. Inhibitory effects of compounds were 125 
normalised as % growth of controls for each assay.  126 
 Invasion inhibition assays with isolated merozoites were conducted as described (4, 127 
37) (for detailed methods see Methods in Malaria Research, 2013 128 
https://www.beiresources.org/Publications/MethodsinMalariaResearch.aspx). Highly 129 
synchronized late-stage schizonts were magnet purified via Macs magnet separation column 130 
(Macs; Miltenyi Biotec) and treated with E64 until mature merozoites were formed. 131 
Merozoites were isolated by membrane filtration and incubated with uninfected RBCs at 132 
0.5% haematocrit and test compounds at indicated concentrations, in 50l volumes.  133 
Estimated number of merozoites per test is approximately 7 X 10
6
 merozoites. Invasion 134 
occurred in agitated conditions for ten minutes, and then in static conditions for a further 20 135 
minutes. Following invasion, cultures were washed twice and returned to culture media. 136 
Parasites were analysed by flow cytometry at 40 hours post invasion as described for growth 137 
inhibition assays.  138 
Modification of heparin-like-molecules 139 
Porcine mucosal heparan sulfates (HS) (HO-10595, a 12-15kDa Highly Sulfated HS, 140 
and HS1098 a15kDa lowly sulfated HS) and 12.5-kDa heparin (MH) were purchased from 141 
Celsus Laboratories, Inc. (Cincinnati, OH, USA). Bovine lung heparin (LH) was from 142 
Calbiochem (Melbourne, Australia), Sulodexide (a low sulfated heparin/low MW dermatan 143 
sulfate, 80:20 ratio) was purchased as Vessel™, manufactured by Alfa Wasserman, Bologna, 144 
Italy, Arixtra (a synthetic heparin pentasaccharide) was from GlaxoSmithKline, Enoxaparin 145 
(a 3kDa low MW heparin) was purchased as Clexane from Sanofi-Adventis and Bemiparin (a 146 
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3kDa low MW heparin) was purchased as Hibro manufactured by Laboratorios 147 
Farmaceuticos Rovi SA. 148 
Heparin compounds were modified with published methods as per following: Glycol-split 149 
heparins and partially (50%) glycol split heparin were prepared by periodate oxidation 150 
followed by NaBH4 reduction as described previously (38-40). Fully de-sulfated heparin was 151 
prepared by the treatment of their pyridinium salts with dimethyl sulfoxide containing 10% of 152 
water at 100
0
C by the method of Nagasawa et al 1977 (41). De-N-sulfated and partially de-N-153 
sulfated heparins were prepared by treatment of their pyridinium salts with dimethyl 154 
sulfoxide containing 5% of methanol for upto 1.5 h at 50
0
C (42).  De-N-sulfated heparins 155 
were N-acetylated by treatment of the heparin with acetic anhydride in 0.5M NaHCO3 at 4
0
C 156 
(43). 2-O-Desulfated heparins and glycol-split heparins were prepared as described by 157 
dissolving the heparin in 0.2M NaOH followed by lyophilization (44), using an adaption 158 
(45). Mucosal heparin (porcine) lacking 6-O sulfate (MH de 6S) was prepared by the 159 
treatment of the pyridinium salt of heparin with N,O-bis(trimethylsilyl)acetamide in pyridine 160 
for 2 h at 60°C   (46). Heparin were decarboxylated by treatment with 1-ethyl-3-(3-dimethyl-161 
aminopropyl) carbodiimide and subsequent sodium borohydride reduction as described 162 
previously ((47), adapted from (48)). 163 
Mucosal heparin (porcine) (5-kDa MH, Smith degradation) was prepared by treatment 164 
of periodate-oxidized mucosal heparin (porcine) with sodium hydroxide, followed by 165 
reduction with sodium borohydride and acid hydrolysis (49). O-acylated derivatives (butyl 166 
and hexyl) of heparin fragments were prepared from their tributylammonium salts in N,N-167 
dimethylformamide using carboxylic acid anhydrides and 4-(dimethylamino)pyridine as 168 
catalyst (50, 51). MH peroxide 3-4kDa MH (H2O2) was prepared by hydrogen peroxide 169 
induced free radical degradation (52). 3kDa MHgc (glycol split mucosal heparin (porcine)) 170 
was prepared by limited (10mins) nitrous oxide degradation of glycol split heparin at pH 4 171 
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(Reaction A, which cleaves both at glucosamine (Glc)NS and GlcNH) using the method of 172 
Lindahl, U et al, 1973 (53) followed by sodium borohydride reduction. 3kDa MH gc-CHO 173 
RT was prepared by the above method without subsequent borohydride reduction to leave a 174 
terminal reactive aldehyde moiety. Hydrazone derivatives of 3kDa MH gc-CHO with 4-175 
phenylsemicarbazide or Benzhydrazide were prepared with a 5 fold molar excess of 4-176 
phenylsemicarbazide or Benzhydrazide in 100mM sodium acetate, pH 6 overnight at room 177 
temperature (20
0
C). Reductive amination of 3kDa MH gc-CHO with Anthranilic acid or 178 
ANTS (1,3,6 triSO3-aminonaphthaline) were prepared with a 5 fold molar excess of 179 
Anthranilic acid or ANTS (1,3,6 triSO3-aminonaphthaline) and a 25 molar excess of sodium 180 
cyanoborahydride (NaBH3CN) in 100mM sodium acetate, pH 6 overnight at room 181 
temperature (20
0
C). 182 
Confirmation of chemical modifications 183 
Following de-N-sulfation of glucosamine residues in the heparin derivatives and their 184 
subsequent re-N-acetylation, the presence or absence of un-substituted glucosamines GlcNH 185 
was determined by degradation of the derivative by nitrous acid at pH 4 using Reaction B 186 
(53) which only cleaves adjacent to unsubstituted glucosamine residues and analysis on 187 
PAGE to determine reduction of size.  The reaction was also quantified by colorimetric 188 
analysis of the resultant anhydromannose residues by reaction with 3-methyl-2-189 
benzothiazolinone hydrazone (54). Size analysis by PAGE was used to demonstrate no 190 
degradation of the modified heparins had occurred following glycol splitting.  The apparent 191 
size of heparin fragments cleaved by peroxide, periodate of nitrous acid cleavage were 192 
determined by PAGE analysis using a mini-gel apparatus (Bio-Rad, Hercules, CA) and 193 
fractionated on 15% resolving gels or 30% Tris-glycine gels (55, 56) using known heparin-194 
derived molecular mass standards of 16.7, 10.6, 6.7 and 3.1kDa which were a generous gift 195 
from Nova Nordisk (Gentofte, Denmark) (57). In addition the structures of carboxyl-reduced 196 
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heparins and de-2-O-sulfate heparins and glycol-split derivatives were analysed by poly-197 
acrylamide gel electrophoresis, and chemical structures determined by 1H NMR 198 
spectroscopy, as previously published (44, 47). 199 
Preparation of oligosaccharide fractions from heparin, heparan sulfate and chondroitin 200 
sulfate E  201 
 Heparin and HS oligosaccharide fragments were prepared as described (58). Briefly, 202 
heparin (200 mg, from porcine intestinal mucosa, Sigma) was incubated with heparin lyase I 203 
(100U , Sigma) and HS (200 mg, from porcine intestinal mucosa, Celsus) with heparinise III 204 
(650 mU, IBEX Technologies, Montreal, Canada) (59) in 5 mM sodium phosphate buffer 205 
(pH 7.1) containing 0.2 M NaCl. The digestion was carried out at 30 
o
C and stopped when 206 
the reaction was 40% complete. After desalting on a short Sephadex G10 column, the 207 
oligosaccharides were fractionated on a Bio-Gel  P-4 column (1.6 × 90 cm) with elution by 208 
0.1 M NH4Cl (pH 3.5). 209 
CSE (2 mg, from squid cartilage, AMS Biotechnology, Abingdon, England) was 210 
digested with 20 mU of chondroitinase ABC (Sigma) in the same phosphate buffer (400 µl) 211 
under identical conditions described above. Oligosaccharide fractionation was carried out on 212 
a Superdex Peptide column (Amersham Biosciences, Little Chalfont, England) eluted by 213 
0.05M ammonium acetate. 214 
 The tetra- and hexsaccharide fractions were subfractionated by strong-anion exchange 215 
on a short cartridge column (HiTrap Q-Sepharose HP, 1 ml, Amersham Biosciences) with 216 
detection at UV 232 nm. Elution was carried out with a linear gradient of NaCl (solvent A, 217 
0.1 M NaCl; solvent B, 1.5 M NaCl; pH 3.5) as described (60). Oligosaccharide subfractions 218 
were collected desalted and freeze-dried before quantitation by carbazole assay for hexuronic 219 
acid content (61).  220 
Heparin binding assays 221 
 10 
For heparin-agarose bead binding assays proteins were extracted from P. falciparum 222 
schizonts into 1% Triton X-100 in PBS as described (62). Proteins from culture supernatants 223 
were collected by allowing highly synchronous schizonts to rupture into protein-free culture 224 
medium and cells removed by centrifugation. Binding of solubilised proteins to heparin-225 
agarose beads was performed as described (7); heparin-agarose beads were washed twice in 226 
PBS, then blocked with 1% casein PBS overnight at 4°C. Schizont protein extracts were 227 
incubated overnight at 4°C with beads containing 0.1% casein and 200 g/ml of test inhibitor 228 
(heparin from Sigma-Aldrich, de-6-OS-heparin from Iduron, Alderley Edgy, U.K.), CSE 229 
from Sikagaku, Tokyo, Japan, and CSC from Sigma-Aldrich), or PBS control (50 l of 230 
packed beads plus 100 l of protein supernatant). Unbound proteins in the supernatant were 231 
collected through Micro Bio-Spin Chromatography Columns (Bio-Rad) and beads washed 5 232 
times with PBS containing 0.1% casein, 1% Triton X-100, and protease inhibitors. Bound 233 
proteins were eluted from beads with 50 l of warmed reducing sodium dodecyl sulfate–234 
polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer. Bound and unbound proteins 235 
were separated by SDS-PAGE under reducing conditions and Western blotted onto 236 
polyvinylidene difluoride membranes for probing with antibodies to detect MSP1-19. MSP1-237 
19 antibodies were raised in rabbits and purified as described (63). 238 
Heparin binding to recombinant MSP1-42 in ELISA was performed as previsouly 239 
described (7). Recombinant MSP1-42 (expressed as His-tagged proteins in E. coli (64), from 240 
Carol Long – National Institute for Health) was coated (1ug/mL) onto 96-well plates (Nunc 241 
Maxisorb) in PBS overnight at 4°C. Plates were washed and blocked with 1% casein, then 242 
incubated with heparin-BSA or BSA, along with increasing concentrations of soluble 243 
inhibitors of heparin, CSC and CSE. Plates were washed, and bound heparin-BSA/BSA was 244 
detected with anti-BSA antibodies (rabbit, Sigma-Aldrich), followed by antirabbit-HRP, and 245 
2,2’- azino-bis(3-ethylbenzthiazoline-6-sulphonic acid; Sigma-Aldrich). All incubations were 246 
 11 
performed in PBS with 0.1% casein and 0.05% Tween 20, 1 hour at room temperature.  247 
 248 
Chemical sulfation of polysaccharides 249 
The sulfation of all non-glycosaminoglycan based carbohydrates was achieved 250 
utilising chlorosulfonic acid, except for those indicted 
†
 and 
$
, where sulfation was carried out 251 
essentially as described by Yoshida et al. using pyridine sulfur trioxide complex and 252 
piperidine-N-sulfonic acid respectively (65). Carbohydrates were purchased from Sigma-253 
Aldrich, Dextra Laboratories, Celsus Glycoscience, Novartis, WAKO Chemicals, and EDQM 254 
(Conseil de l’Europe) as indicated in Supplementary Table S2. Precursor carbohydrates 255 
requiring sulfation (500 mg) were added to pre-chilled dry pyridine (VWR) in advance of the 256 
addition of chlorosulfonic acid (1:16 v/v; VWR). The mixture was incubated at 95°C for 2 257 
hours prior to cooling with the assistance of an ice-bath. Sodium hydroxide (10 M; Fisher) 258 
was added to the mixture with stirring until precipitation occurred. The contents were 259 
subsequently transferred to ice cold ethanol (VWR) pre-saturated with sodium acetate 260 
(VWR). The precipitate was washed extensively before dissolution in and dialysis (3.5 kDa 261 
cut-off; Medicell Membranes) against ddH2O. The dialysed solution was frozen and 262 
lyophilised before size exclusion chromatography was performed using HPLC grade H2O 263 
(Fisher) and a pre-packed PD-10 column (GE Healthcare), as per the manufacturer's 264 
instructions. Sulfation of highly inhibitory compounds was confirmed by recording 265 
attenuated total reflectance FTIR spectra using a Nicolet iS5 IR-TF (Thermo Fisher) 266 
spectrometer at the Institute of Science and Technology for Medicine facility of Keele 267 
University, scanning in the 4000–400 cm-1 region with a spectral resolution of 2 cm-1 over 32 268 
scans (Supplementary Figure 1). A background air spectrum was obtained and subtracted 269 
from all spectra. All carbohydrate spectra were recorded using ThermoFisher Omnics 270 
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software. In order to further improve the comparison between samples, the mean of 5 FTIR 271 
spectra per sample was normalized to relative absorbance (i.e. dividing the absorbance value 272 
of each point of the spectrum by the ratio of a mutually common and identical spectral region 273 
for each precursor and modified polysaccharide pair). First derivatives of all spectral data for 274 
precursor/modified polysaccharide pairs were plotted and overlaid using Prism software 275 
(GraphPad Software, Inc.). 276 
Assessing anticoagulation activity by activated partial thromboplastin time 277 
Anticoagulation activity of a subset of sulfated polysaccharides, which had high 278 
merozoite inhibitory activity, was assessed by measuring activated partial thromboplastin 279 
time. Cuvettes, ball bearings, 50 mM calcium chloride and test compounds (or controls) were 280 
all pre-warmed to 37°C using a Thrombotrack Solo coagulation analyzer (Axis-Shield). Into 281 
a cuvette, 50 μl of normal human citrated plasma, 25 μl of aqueous test sample or an HPLC 282 
grade water control and 50 μl Pathromtin SL reagent (Siemens) were incubated for 2 minutes 283 
at 37°C. The time for clot formation to occur was ascertained immediately following the 284 
addition of 25 μl of a 50 mM calcium chloride solution to the cuvette. 285 
Statistical analysis 286 
Statistical analysis was performed in Graph Pad Prism 6. Comparison of activity 287 
between individual parent and their modified HLMs in growth inhibition assays was 288 
performed using paired t-tests for each combination of compounds. P values were adjusted 289 
using the   Holm-Sidak method within each individual modification, to decrease the risk of 290 
false discovery rates due to performing multiple comparisons. Overall impact of a specific 291 
modification (for example, de-2-sulfation) was assessed by Wilcoxon matched-pair sign rank 292 
test of all compounds with parent and modified compounds paired. For all comparisons 293 
p<0.05 is considered statistically significant. 294 
  295 
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RESULTS  296 
Heparin can be modified to increase inhibitory activity and remove anticoagulant 297 
activity 298 
Due to the high anti-coagulant activity of heparin, it cannot be used directly as an anti-299 
malarial agent. Different modifications of heparin compounds can reduce the off-target 300 
effects of compounds such as anticoagulation activity, and increase bioavailability and half-301 
life. We investigate a panel of compounds comprising modified heparin and HLMs for 302 
inhibitory activity. These included HLMs with non-sulfated uronic acid ring opened and 303 
cleaved at the diol site after periodate oxidation treatment; HLMs with carboxyl groups of 304 
hexuronic acid residues reduced and HLMs with hydroxyl groups acylated (for the full list of 305 
compounds see Table S1). Periodate oxidation of non-sulfated uronic acid residues, which 306 
has been reported to abolish anticoagulation activity (40), increased the activity of some but 307 
not all compounds (compounds with improved inhibition following treatment – mucosal 308 
heparin de2S, mucosal heparin de6S, mucosal heparin 3kDa length; compounds with 309 
decreased inhibition following treatment – bemiparin and fondaparinux; overall impact of 310 
periodate treatment p=0.195, Table 1). The molecular basis for the increased activity is 311 
currently unknown, but one possibility is that increased conformational flexibility of these 312 
modified compounds may allow for higher capacity to bind merozoite target antigens. We 313 
also assessed the impact of esterification of hydroxyl groups by testing inhibitory activity of 314 
mucosal heparin (porcine) that was both periodate treated and esterified (MH gc butyrate). 315 
Compared to non-esterified parent compound (MH gc), esterification of hydroxyl groups 316 
resulted in an 32% increase in inhibitory activity compared to parent compound (% inhibition 317 
at 20 g/ml – MH gc; 65% s.e.m 4.7%. MH gc butyrate; 97% s.e.m. 0.1%, p<0.001). Indeed, 318 
periodate treated and esterified heparin was one of the most highly inhibitory compounds 319 
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tested. These results demonstrated the potential for developing compounds with increased 320 
inhibitory activity based on heparin and modified molecules. 321 
Inhibitory activity of HLMs requires sulfation and activity occurs across a range of 322 
sizes 323 
We next compared parent and modified compounds to identify features important in 324 
inhibitory activity. Consistent with our prior reports (7), sulfation was a key feature of 325 
inhibitory compounds, with reduced activity in de-O- and -N-sulfated compounds compared 326 
to the parent compounds (overall impact of de-sulfation p<0.0001, Table 2). Further, overall 327 
longer chain heparin molecules (>3-25kDa) showed a trend towards having higher inhibitory 328 
activity than shorter chain compounds (3kDa) (Mann-Whitney test p=0.06, Table 3). 329 
However, inhibition was not strictly size dependent; low molecular weight heparin such as 330 
enoxaparin (~3kDa) had comparable activity to full-length heparin (3-25 kDa) (Table 3). 331 
Further, a number of size fractionated highly sulfated small HLMs (di-, tetra- and 332 
hexasaccharides) had substantial growth inhibitory activity, including HS derived 333 
hexasaccharides (Figure 1).  However, it should be noted that heparin oligosaccharides <6-334 
mers in general have little inhibitory activity (7), suggesting that inhibition by the 335 
hexasaccharides tested here may be due to specific sulfation conformation or patterns of these 336 
compounds that convey higher than usual inhibitory activity.  337 
Highly sulfated chondroitin sulfates inhibit P. falciparum growth 338 
Having shown that a key feature of inhibitory HLMs is a high level of sulfation, we 339 
investigated whether highly sulfated CS compounds inhibited merozoite invasion. We have 340 
previously shown that CSC and CSA with low degree of sulfation are non-inhibitory (7). 341 
Here we tested CSD (low level sulfation) and highly sulfated CSE and CSB. CSD has 342 
sulfation at uronate 2S, and galactosamine 6-S, CSE at 4S and 6S of galactosamine and CSB 343 
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2S at uronate and either 4S or 6S at galactosamine. CSE had substantial inhibitory activity 344 
(IC50 approximately 25 g/ml) (Figure 2a). Highly sulfated CSB-2,6-OS also had modest 345 
inhibitory activity at high concentrations, whereas CSD was not inhibitory. This suggests 346 
that, as for K5-heparin like molecules tested previously (7), location of at least 2 sulfates 347 
together on a single oligosaccharide enhances inhibitory activity. To further investigate the 348 
inhibitory activity of CSE a number of CSE hexasaccharides with different sulfation levels 349 
were tested in invasion inhibition assays with purified merozoites. This assay differs from 350 
standard growth assays as compounds are only incubated with merozoites and RBCs for 30 351 
minutes while invasion is occurring, compared to growth assays which incubated drugs with 352 
cultures over the course of the entire 48 hour blood-stage development cycle and invasion 353 
inhibition assays are more sensitive that standard growth assays (37). Inhibition appeared to 354 
increase with sulfation level; 50% inhibition was observed with CSE hexasaccharides having 355 
7 sulfate groups, when tested at 100g/ml (Figure 2b). However, CSE hexasaccharides had 356 
no activity in standard growth inhibitory assays at these concentrations, possibly due to short 357 
chain CS oligosaccharides having too few sulfate groups to mediate complete inhibition. The 358 
discrepancy between standard growth and invasion inhibition assays is likely due to the 359 
increased sensitivity of invasion assays that use purified merozoites (37), suggesting that the 360 
inhibitory activity of compounds is at the threshold of that detected by standard growth 361 
assays. 362 
To characterize the functional mechanism of CSE inhibition, schizont rupture and 363 
merozoite invasion in the presence of CSE was analysed via flow cytometry with 364 
differentiation of parasite stages with ethidium bromide staining (7) and live video imaging 365 
(16, 34). As with the inhibitory mechanism of heparin (7), cultures incubated with CSE 366 
showed evidence of a slight delay of schizont rupture compared to uninhibited cultures 367 
(Figure 3a), but the predominant mechanism of inhibition appeared to be merozoite invasion 368 
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inhibition, resulting in very low rates of ring formation (Figure 3b).  Live-video imaging 369 
demonstrated that CSE prevented the invasion of merozoites into RBCs at early invasion 370 
steps; we observed schizont rupture, merozoite dispersal and initial contact of merozoite with 371 
RBCs. However, no oscillatory deformation was observed and merozoites dissociated from 372 
the RBC surface without clear re-orientation of merozoites and echinocytosis of the RBC 373 
(Figure 3c). A single invasion event was observed in 6000 seconds of observation, over 9 374 
schizont rupture events; whereas 21 invasion events in 13 schizont ruptures and 5442 seconds 375 
of filming was recorded in uninhibited cultures. Having observed that the CSE inhibitory 376 
mechanism appeared similar to heparin, we tested the ability of CSE to disrupt MSP1 binding 377 
to heparin, a target of heparin inhibition (7). CSE was unable to disrupt the binding of native 378 
or recombinant MSP1-42 to heparin (Figure 3d/e). This suggests that CSE may be inhibiting 379 
initial steps of merozoite invasion via targeting alternative merozoite surface proteins or 380 
invasion ligands.  381 
Identification of inhibitory sulfated carbohydrates 382 
Having shown that inhibitory activity appears to be reliant on sulfation level and that 383 
longer chain lengths are needed for substantial activity, we tested a large panel of 384 
polysaccharides to test the impact of sulfation and re-sulfation on inhibitory activity, and to 385 
attempt to identify polysaccharides that have potential to be used as the base compounds for 386 
novel drug development (for the full list of compounds and sources see Table S2). 387 
Polysaccharides were tested in standard growth inhibitory assays at 2, 10, 20 and 100 g/ml. 388 
We tested 87 compounds prepared from a variety of sources with different levels and patterns 389 
of sulfation. Initial testing identified 50 compounds with inhibitory activity of greater than 390 
20% when tested at 20g/ml or lower, with 14 compounds being highly inhibitory at 391 
concentrations of 2g/ml (Table 4). The other 37 compounds showed weak or no inhibitory 392 
activity and were not further studied (Table 5). The stage-specificity of inhibition of 393 
 17 
merozoite invasion of inhibitory compounds with an IC50<10g/ml in growth inhibition 394 
assays was confirmed in direct invasion inhibition assays using purified merozoites (Figure 395 
4) (4, 37). The most highly inhibitory compounds with an IC50 of <2 g/ml determined in 396 
standard growth inhibition assays and that had confirmed invasion inhibitory activity were 397 
chemically over-sulfated i-carrageenan, inulin sulfate, propyleneglycol alginic sulfate, 398 
psyllium sulfate, scleroglucan sulfate, tragacanth sulfate, xylan sulfate (also known as 399 
pentosan polysulfate), chemically over-sulfated -carrageenan, pullulan sulfate and 400 
chemically over-sulfated dextran. De-N-acetylated dermatan sulfate and de-N-acetylated 401 
heparin (bovine) also had inhibitory activity in standard 48 hour growth assays; however, this 402 
was not confirmed in direct invasion inhibitory assays, suggesting that inhibition seen in 403 
growth assays was not specific to merozoite invasion and may be due to non-specific activity 404 
of the sample or other mechanisms of inhibition. The anti-coagulation activity of highly 405 
inhibitory compounds was tested by assessing activated partial thromboplastin time. All 406 
compounds had reduced anti-coagulation activity compared to heparin (Supplementary Table 407 
3), indicating that these compounds may be more suitable base compounds for future drug 408 
development.  409 
 410 
 Discussion 411 
Merozoite invasion of the RBC is a critical step during parasite infection, and an 412 
attractive target for therapeutics that may have potential for use in combination with current 413 
antimalarials (4, 5, 7). While heparin has been used as adjunctive treatment for malaria 414 
complications, its use as a therapeutic in malaria is no longer recommended due to the risk of 415 
serious bleeding-related side effects from high anti-coagulant activity (66). Here we identify 416 
chemical modifications of heparin that increase inhibitory activity of merozoite invasion, 417 
 18 
such as periodate oxidation of non-sulfated uronic acid residues and treatment to esterify 418 
hydroxyl groups. Importantly, periodate treatment has been reported to greatly reduce 419 
anticoagulation activity of heparin (40), suggesting that the development of HLMs that have 420 
high anti-malarial activity and reduced anticoagulation maybe possible. Similarly treated 421 
HLMs have been recently tested for inhibition of lung cancer growth in mice and have no 422 
anticoagulation activity nor toxicity in heart, liver, kidney or lung tissue (67). On the other 423 
hand, de-sulfation and de-N-acetylation significantly decreased inhibitory activity, consistent 424 
with sulfation mediating inhibition and our prior published studies (7). We demonstrated that 425 
highly sulfated heparin and chondroitin sulfate compounds have substantial inhibitory 426 
activity against P. falciparum merozoite invasion. Short chain heparins and heparin and HS 427 
tetra- and hexasaccharides, along with chemically over sulfated CSB polysaccharides and 428 
naturally sulfated CSE polysaccharides and oligosaccharides were identified with inhibitory 429 
activity.  430 
As with heparin-like compounds, chondrotin sulfate compounds have been proposed 431 
as the basis for drug development with a number of applications, suggesting that these 432 
compounds may have use as base molecules for anti-malarial drug development (68).  CSE 433 
demonstrated significant inhibitory activity that appeared to be targeting initial contact events 434 
of merozite invasion, with a small inhibitory activity against schizont rupture, similar to the 435 
previously reported mechanisms of inhibition of heparin (7). However, CSE was unable to 436 
inhibit the binding of MSP1-42, which was previously identified as a target of heparin 437 
inhibition (7), suggesting that CSE may target another merozoite surface protein. Multiple 438 
merozoite microneme and rhoptry proteins have been reported to bind heparin (17-19). 439 
However, the timing of CSE inhibitory activity is at the initial contact/pre-invasion steps 440 
prior to substantial deformation of the RBC that is triggered by these proteins (16), which 441 
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suggests that the CSE inhibitory function is targeting merozoite surface proteins that are 442 
thought to be involved in these initial stages of invasion.  443 
The targeting of inhibitory HLMs in preventing the early stages of invasion suggests 444 
that HLMs inhibit the binding of the merozoite to the RBC by disruption of receptor-ligand 445 
interaction to sulfated receptors. These initial contact events are thought to be mediated by 446 
multiple merozoite surface proteins, via low affinity interactions with the RBC surface. As 447 
many of these interactions are likely to be to sulfated surface receptors, the ability of HLMs 448 
to disrupt multiple interactions, across multiple invasion steps is likely to ensure the efficacy 449 
of HLMs across all parasite strains, and limit the emergence of drug resistance. Indeed, 450 
previous attempts to induce heparin-resistance in vitro have failed (7). It is possible that 451 
HLMs are active at different stages of the parasite life cycle, as suggested by the small 452 
inhibitory effect on schizont rupture. It is possible that HLMs may also function by coating 453 
the RBC surface, rather than the merozoite, further contributing to the inability to induce 454 
resistant parasites.  455 
A major priority for future development of drugs based on this approach is the 456 
generation of compounds with much greater potency. This might be achieved through 457 
chemical modification of compounds, or through the synthesis of mimetics with a similar 458 
mechanism of action. Further, inhibitory HLMs and the identified CS oligosaccharide 459 
compounds with inhibitory activity may in the future be the basis for the development of 460 
modified HLMs with increased bioavailability and improved inhibition activity. 461 
Modifications may include those identified above, including periodate treatment and 462 
esterification. The activity of 4-mer and 6-mer oligosaccharides suggests it may be possible 463 
to identify and optimise short saccharides with high invasion inhibition activity; while our 464 
data suggests that a 6-mer oligosaccharide is needed for inhibitory activity of heparin, 465 
stachyose sulfate (a tetramer) was also identified as a strong inhibitor of invasion. At the 466 
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present time, there is little information available concerning the oral availability of the active 467 
compounds reported here. However, there have been efforts to improve the oral availability 468 
of heparin derivatives (reviewed in (69)), and the expectation is that such approaches would 469 
also prove effective for these compounds if required. Among the successful methods that 470 
have been reported are the use of conjugates with polycarbophil-cycteine 471 
(70) anddeoxycholic acid (71). Further, the use of nanoparticles has been reported to improve 472 
both oral availability, as well as prolong HLM drug activity (72) which may allow heparin 473 
based compounds to remain active for multiple parasite life cycles. 474 
Alternatively, inhibitory sulfated polysaccharides identified here from testing a large 475 
panel of sulfated polysaccharides prepared from a wide range of sources may be used as base 476 
molecules for future drug development.  We identify a number of highly inhibitory 477 
compounds with estimated IC50 <10g/ml targeting merozoite invasion; agarose sulfate, 478 
alginic sulfate, amylopectin sulfate, arabic sulfate, cyclodextrin sulfate, chemically over-479 
sulfated i-carrageenan, -carrageenan, chemically oversulfated -carrageenan, dextran 480 
sulfate, dextrin sulfate, gellan sulfate, ghatti sulfatie, glycogen sulfate, guar sulfate, inulin 481 
sulfate, konjac glucomannan sulfate, levan sulfate, paramylon sulfate, penoxyacetyl cellulos 482 
suflate, pullulan sulfate, propyleneglycol alginic sulfate, psyllium sulfate, scleroglucan 483 
sulfate, tragacanth sulfate, taramind sulfate, welan sulfate and xylan sulfate. While dextran 484 
sulfates, carrageenans, gellan sulfates and xylan sulfate have been previously reported to 485 
inhibit P. falciparum in vitro growth (13, 73-75), the remaining compounds have not been 486 
previously identified as P. falciparum inhibitors. All of these compounds had greater 487 
inhibitory activity than heparin, with IC50 values less than 10 g/ml. Importantly, these 488 
compounds have reduced anticoagulation potential than heparin, suggesting that these 489 
compounds are more suitable for future drug development as they would avoid bleeding-490 
related complications. Base compounds may be extracted from natural sources for future drug 491 
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development. Indeed, the extraction of sulfated seaweed polysaccharides such as 492 
carrageenans from algae has become routine due to their broad application (reviewed in 493 
(76)). Compounds identified here may also be used as the basis for future structure/functional 494 
studies and the development of small molecule inhibitors that can be synthetically developed. 495 
The synthetic and chemically modified non-glycosaminoglycan based compounds 496 
investigated in this study have the additional advantages of being isolated from non-497 
mammalian sources, circumventing possible concerns with prion diseases or the provenance 498 
of supplies of mammalian origin. This is of particular relevance following recent reports 499 
regarding the contamination of pharmaceutical grade heparin (77, 78). Further, while this 500 
work has focused on the inhibition of merozoite invasion, compounds identified here may 501 
also have further therapeutic benefit by disrupting parasite sequestration and rosette 502 
formation (15, 20-26). The combined ability to disrupt two separate stages of the parasite 503 
life-cycle increases the time window of activity of any dual acting compounds. Further 504 
studies are needed to assess whether the structural features required for merozoite invasion 505 
inhibition are also important in sequestration and rosette inhibition. However, the pursuit of 506 
sulfate HLMs as base compounds for novel drug development is supported by several reports 507 
of the inhibitory capacity of similar compounds to both disrupt parasite invasion as well as 508 
sequestration in in vivo models (11, 14, 25, 73, 79, 80). 509 
In conclusion, this work has identified a number of carbohydrate compounds with 510 
high inhibitory activity against merozoite invasion of RBCs and a number of modifications 511 
were identified that enhance inhibitory activity. Optimisation of highly inhibitory compounds 512 
based on these observations may provide opportunities for the development of novel 513 
therapeutics useful in combating malarial disease.  514 
 515 
LIST OF ABBREVIATIONS: 516 
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CS – chondroitin sulfate 517 
gc – glycol splitting 518 
Glc – glucosamine 519 
HLMs – heparin-like-molecules 520 
HS – heparan sulfate 521 
LH – lung heparin 522 
MH – mucosal heparin 523 
MSP1 – merozoite surface protein 1 524 
RBC – red blood cell 525 
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Figure legends: 814 
Figure 1: Growth inhibitory activity of fractionated heparin and heparan-sulfate 815 
compounds.  816 
Fractionated heparin and heparin sulfate tetra- and hexa-saccharides were tested for growth 817 
inhibitory activity in two cycle assays. Data are mean ± s.e.m. from two assays in duplicate. 818 
Abbreviations: HS, heparan-sulfate, hep heparin, 4mer tetrasaccharide, 6mer 819 
hexasaccharides. N-sulfation is indicated as Ac1-2, while lack of N-sulfation is Ac0. O-820 
sulfation is indicated as S0-9. Compounds listed with * are different preparations of the same 821 
fraction. 822 
 823 
Figure 2: Identification of chondroitin sulfates with inhibitory activity against P. 824 
falciparum merozoite invasion. 825 
A. CSD, CSE and highly sulfated CSB polysaccharides were tested in growth inhibition 826 
assays at concentrations 0-100 g/ml. Data are means  s.e.m. of three assays in duplicate. B. 827 
Fractionated CSE hexasaccharides were tested in invasion inhibition assays. Degree of 828 
sulfation is 5, 6, or 7 sulfate groups per molecule. Data are mean  range of one assay in 829 
duplicate. 830 
 831 
Figure 3: CSE disrupts initial contact of the merozoite to the RBC, but not heparin 832 
binding to MSP1-42. 833 
Flow cytometry of late stage parasite cultures with parasite stages differentiated based on 834 
ethidium bromide staining was used to track parasite rupture as % schizonts (A), and 835 
merozoites invasion as % ring forms (B) in CSE (100μg/ml and PBS/uninhibited cultures. 836 
 31 
After 3 hours of incubation there were increased frequencies of schizonts and decreased ring 837 
forms in CSE incubated cultures. Data are mean  s.e.m of two assays performed in 838 
duplicated, * p<0.05. (C) Live video microscopy of merozoite invasion in the presence of 839 
CSE. Merozoites were able to make initial contact with the RBC, but contact was not 840 
sustained, and merozoites disassociated from the RBC surface. Seconds is indicated in lower 841 
right corner, and the white arrow highlights a single merozoite that attached and then 842 
disassociated from the RBC. (D) Heparin-bead binding assays with P. falciparum protein 843 
extract. Protein extract was incubated with heparin-beads along with soluble inhibitors as 844 
indicated. Unbound and bead-bound fractions were probed for MSP1-42 binding via western 845 
blots. MSP1-42 was found in the unbound fraction when incubated with heparin as a soluble 846 
inhibitor, indicating that soluble heparin was able to out-compete binding. However, MSP1-847 
42 was found in the bound fraction when incubated with soluble de-6-OS heparin, CSE or 848 
CSC indicating that this compounds were not able to compete with heparin-binding. (E) 849 
MSP1-42 coated on ELISA plates was incubated with heparin-BSA along with soluble 850 
heparin, CSC and CSE at increasing concentrations. Binding of heparin BSA was detected 851 
with anti-BSA antibodies. Soluble heparin, but not CSE or CSC inhibited binding of heparin-852 
BSA to MSP1-42. 853 
 854 
Figure 4: Invasion inhibition activity of sulfated polysaccharides. 855 
Highly active HLMs and sulfated carbohydrates were tested in invasion inhibition assays to 856 
confirm activity against merozoite invasion. All compounds were tested at 10 g/ml. Data are 857 
expressed as inhibition from one assay in duplicate, relative to PBS as a reference control. 858 
Three CSC negative controls were included in assay and all were non inhibitory (data not 859 
shown). 
†
 Prepared using pyridine sulfur trioxide complex.
 $
 Prepared using piperidine-N-860 
sulfonic acid. 861 
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 862 
Table 1: Effect of glycol splitting by periodate treatment on inhibitory activity of 863 
heparin against merozoite invasion in growth inhibition assays. 864 
 865 
  Inhibition % (s.e.m.)   
Modification Parent compounds Parent Modified 
Gain of 
inhibition 
Glycol split MH 68 (7) 77 (9) 9 
 MH de2S 27 (2) 54 (6) 27 * 
 MH de6S 5 (1) 61 (5.8) 56 * 
 MH 3kDa 37 (2) 70 (8) 33 * 
 MH H2O2  57 (4) 62 (4) 5 
 Enoxaparin  64 (5) 80 (3) 14 
 Bemiparin 45 (2) 31 (5) - 14 
 Fondaparinux 34 (0) 11 (4) - 23 *  
 866 
A panel of modified heparin compounds was tested for inhibition of P. falciparum in 867 
standard growth inhibition assays at 100 g/ml. Comparisons were made between parent and 868 
periodate treated compounds. Gain of inhibition is calculated as the (inhibition of the 869 
modifed – inhibition of parent). Positive values indicate increased inhibitory activity in the 870 
modified compound compared to the parent. Negative values indicate reduced inhibitory 871 
activity in the modified compound compared to the parent. Significant differences in 872 
inhibitory activity between parent and modified compounds are indicated with * (p>0.05, 873 
corrected for multiple comparisons by Holm-Sidak method).  Data is mean inhibition ± s.e.m. 874 
of two assays in duplicate. Abbreviations: MH, mucosal heparin (porcine);  875 
 33 
 876 
 877 
  878 
 34 
Table 2: Effect of de-2, -6, or –N sulfation (with and without re-NAc) on inhibitory 879 
activity of heparin against merozoite invasion in growth inhibition assays 880 
  Inhibition % (s.e.m.)  
Modification Parent compounds Parent Modified 
Loss in 
inhibition 
De-2-S % MH  68 (7) 26 (2) 42 *  
 MH gc  77 (9) 54 (6) 23 
 LH  74 (7) 49 (0) 25 
 MH 5kDa  75 (6) 45 (4) 30 
 MH 5kD gc  73 (8) 41 (1) 32 
 MH H202 gc  62 (4) 7 (1) 55 * 
 MH 3kDa  37 (0) 15 (4) 22 * 
 MH 3kDa gc  70 (8) 11 (5) 59 * 
De-6S MH 68 (7) 5 (1) 63 * 
 MH gc  77 (9) 61 (6) 16  
 MH gc de2s  54 (6) 21 (1) 33 * 
 MH 5kDa  75 (6) 41 (4) 34 * 
De-NS (NH) % MH gc  77 (9) 17 (4) 60 * 
Partial NAc % MH gc  77 (9) 62 (6) 15 
 MH 5kD gc 73 (8) 64 (2) 9 
 MH H202  57 (4) 15 (3) 42 * 
 MH H202 gc de2S  7 (1) 3 (1) 4 
 MH gc de2s  54 (6) 24 (8) 30 
 MH de2S  26 (2) 28 (3) -2 
 LH de2S  49 (0) 8 (6) 41 * 
Total NAc MH  68 (7) 47 (4) 21 
 MH de2S  26 (2) 23 (2) 3 
 MH gc 77 (9) 8 (3) 69 * 
 MH gc de2S 54 (6) 0 (3) 54 * 
 35 
 LH de2S  49 (0) -8 (6) 57 * 
 881 
Modified heparin compounds were tested for inhibition of P. falciparum in growth inhibition 882 
assays at 100 g/ml. Comparisons were made between parent and de-sulfated modified 883 
compounds. In the majority of cases de-sulfation result in reduction in inhibition activity. 884 
Loss of inhibitory activity is calculated as the (inhibition of the parent – inhibition of 885 
modified). Positive values indicate reduced inhibitory activity in the modified compound 886 
compared to the parent. Negative values indicate increased inhibitory activity in the modified 887 
compound compared to the parent. Significant differences in inhibitory activity between 888 
parent and modified compounds are indicated with * (p>0.05, corrected for multiple 889 
comparisons by Holm-Sidak method). Significant difference of modification across groups of 890 
modified compounds is indicated with %. Data is mean inhibition ± s.e.m. of two assays in 891 
duplicate.. Abbreviations: MH, mucosal heparin (porcine); LH, lung heparin (bovine), gc, 892 
glycol splitting. 893 
894 
 36 
Table 3: Invasion inhibition activity of heparin compounds of different sizes against 895 
merozoite invasion in growth inhibition assays. 896 
Size group Compounds (size estimate) 
Inhibition 
% (s.e.m.) 
Long chain  Mucosal heparin (>3-25kDa) 68 (7) 
 Lung heparin (>3-25kDa) 74 (5) 
 Mucosal heparin 5kDa (>3-8kDa) 75 (4) 
Short chain Mucosal heparin (3kDa) 37 (0) 
 Enoxaparin (3kDa) 64 (6) 
 Bemiparin (3kDa) 45 (3) 
 Fondaparinux (3kDa) (pentasaccharide) 34 (0) 
 897 
Heparin compounds of different oligosaccharide chain length were tested for inhibition of P. 898 
falciparum in growth inhibition assays at 100 g/ml. Data is mean inhibition ± s.e.m. of two 899 
assays in duplicate.  Mucosal heparin is from porcine and lung heparin is from bovine 900 
sources.901 
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Table 4: Inhibitory activity of heparin like molecules and sulfated polysaccharides of merozoite invasion in growth inhibition assays 902 
Very strong inhibitors 
Estimated IC50 
 <2g/ml 
Inhibition  
% (s.e.m) 
(2 g/ml) 
Strong inhibitors 
Estimated IC50 
2-10 g/ml 
Inhibition 
% (s.e.m.) 
(10 g/ml) 
Moderate inhibitors 
Estimated IC50 
10-20 g/ml 
Inhibition 
% (s.e.m) 
(20 g/ml) 
 Inulin sulfate 93 (4.5)  Cyclodextrin sulfate 96 (2) Karaya sulfate 97 (0.1) 
* De-N-Ac Hep (bovine) 92 (2.5)  Welan sulfate 96 (1.3) Dextrin sulfate 96 (0) 
 Dextran sulfate† (73, 74) 90 (0.3)  Agarose sulfate 95 (1.4) Fucogalactan sulfate 96 (1) 
 Xylan sulfate# 86 (6.4)  Arabic sulfate$ 95 (1.6) Arabic sulfate 94 (1) 
 Propyleneglycol alginic sulfate 77 (3.6)  Glycogen sulfate 95 (2.5) Carboxymethyl cellulose sulfate 94 (1.1) 
 chemically over-sulfated N-Ac Hep 72 (1.3)  Penoxyacetyl cellulose sulfate 95 (2.3) Amylose sulfate 86 (2.1) 
* De-N-Ac Hep (porcine) 72 (1.3)  chemically over-sulfated free amino hep 95 (2.5) Pectin sulfate† 84 (2) 
* De-N-Ac Dermatan S  67 (13.7)  Konjac glucomannan sulfate 95 (2.8) Locust bean gum sulfate 79 (3.7) 
   Levan sulfate 94 (3.2) Chitosan sulfate 61 (2.7) 
 chemically over-sulfated  - Carrageenan †, (13, 
75) 
65 (10.4)  Pullulan sulfate† 94  (1.2) Guar sulfate 59 (3.6) 
 Tragacanth sulfate 64 (11.7)  Taramind sulfate 94 (1.5)   
 chemically over-sulfated i-carrageenan (13)  64 (6.4)  Ghatti Sulfate 92 (2.8)   
Scleroglucan sulfate 55 (8)  -carrageenan $, (13, 75) 90 (2)   
   Paramylon sulfate 90 (1.9)   
      
 38 
   Psyllium seed gum sulfate 89 (2)   
  Stachyose sulfate 89 (4.6)   
   Agarose sulfate† 87 (2.6)   
 
  chemically over-sulfated κ-carrageenan $ (13, 
75) 
85 (2.9) 
 
 
   Gellan sulfate (81) 82 (9.6)   
   Amylopectin sulfate 74 (1)   
  * Tara sulfate 71 (3.7)   
   Heparin (Bovine lung) (7) 70 (8.1)   
   Guar sulfate† 68 (7.1)   
   Alginic sulfate 62 (11)   
   Psyllium sulfate 56 (10)   
   Dextrin sulfate 56 (9.1)   
 903 
 39 
Compounds were tested in growth inhibitory assays at 2, 10 and 20 g/ml. Inhibitory compounds are listed according to their estimated IC50 and 904 
ordered based on inhibitory activity. Inhibition activity at 2, 10 and 20 g/ml is as indicated. Data is mean of two assays performed in duplicate 905 
± s.e.m. Highly inhibitory compounds were additionally screened in invasion inhibition assays with purified merozoites to confirm targeting of 906 
merozoite invasion. Compounds marked with * were non-inhibitory in invasion inhibition assays suggesting that these samples may contain a 907 
non-specific growth inhibitory substance or act through a mechanism separate to invasion inhibition.
 #
 Xylan sulfate is also known as pentosan 908 
polysulfate. 
†
 Prepared using pyridine sulfur trioxide complex. 
$
 Prepared using piperidine-N-sulfonic acid. Abbreviations: Hep, heparin. Where 909 
published previously, references are listed beside compounds.910 
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Table 5: Carbohydrate compounds with weak or no inhibitory activity against 911 
merozoite invasion in growth inhibition assays 912 
 913 
Weakly inhibitory  Non-inhibitory  
Estimated IC50 
20-100 g/ml 
Inhibition 
% (SD) 
(100 g/ml) 
<20% inhibition at 100 g/ml Inhibition % 
(SD)  
(100 g/ml) 
Alginic sulfate$ 35 (0) Chitosan Sulfate† 19 (2) 
Ardeparin 62 (1) CSA 1.2 (3) 
Certoparin 65 (4) CSC (7) 0.8 (2) 
Curdlan sulfate (10) 30 (0) Curdlan sulfate$, (10) 11 (0) 
Dalteparin (LMW heparin) 70 (5) Danaparoid 4 (1)  
De-N-sulfated enoxiparin 66 (0) De-N-Ac Chitosan 0 (1) 
Enoxiparin (LMW heparin) 63 (5) De-N-Ac CSC 0 (1) 
Ghatti Sulfate† 73 (3) Ethyl cellulose sulfate 4 (8) 
Hypromellose sulfate 20 (1) Gum Rosin sulfate 3 (2) 
Locust bean gum sulfate†  46 (3) Hyaluronic acid 0 (3) 
N-Ac enoxiparin 21 (1) Heparan sulfate 6 (6)  
Pectin sulfate$ 28 (3) Hydroxyethyl cellulose sulfate 0 (0) 
Pullulan sulfate 41 (6) Methylcellulose sulfate 0 (0) 
Reviparin 60 (0) N-propylated heparin (porcine) 3 (1) 
Sulodexide 37 (2) Propylmethyl sulfate 0 (3) 
Tinzaparin 70 (6) Scleroglucan Sulfate† 0 (0) 
Tylose sulfate 23 (1) Starch sulfate 13.3 (1) 
  Storax sulfate 10 (1) 
  Xanthan sulfate 6 (3) 
    
 914 
 41 
Compounds were tested in growth inhibition assays at 2, 10, 20 and 100 g/ml. Weakly 915 
inhibitory and non-inhibitory compounds are listed according to estimated IC50 of between 20 916 
and 100 g/ml or non-inhibitory if <20% growth inhibition at 100g/ml. Inhibition activity at 917 
100 g/ml is indicated. Data are means of two assays performed in duplicate ± s.e.m.  918 
Abbreviations: CS, chondroitin sulfate, Ac, acetylated. 
†
 Prepared using pyridine sulfur 919 
trioxide complex.
 $
 Prepared using piperidine-N-sulfonic acid. 920 
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